Publications by authors named "Elvira Delcuratolo"
Background: Sacubitril/valsartan (S/V) is a cornerstone treatment for heart failure (HF). Beneficial effects on hospitalization rates, mortality, and left ventricular remodeling have been observed in patients with heart failure and reduced ejection fraction (HFrEF). Despite the positive results, the influence of S/V on renal function during long-term follow-up has received little attention.
View Article and Find Full Text PDFIn the last decades, several classifications and definitions have been proposed for advanced heart failure (ADVHF) patients, including clinical, functional, hemodynamic, imaging, and electrocardiographic features. Despite different inclusion criteria, ADVHF is characterized by some common items, such as drug intolerance, low arterial pressure, multiple organ dysfunction, chronic kidney disease, and diuretic use dependency. Additional features include fatigue, hypotension, hyponatremia, and unintentional weight loss associated with a specific laboratory profile reflecting systemic multiorgan dysfunction.
View Article and Find Full Text PDFArticle Synopsis
- Heart failure patients are typically categorized based on ejection fraction to enhance treatment strategies, with a need for additional classification by gender due to observed differences in disease progression between men and women.
- Women are often underrepresented in clinical trials, limiting the understanding of how heart failure affects different sexes, despite findings that onset and progression of the disease can vary significantly.
- The review discusses how sex hormones and risk factors might influence heart failure mechanisms, highlighting the need for tailored approaches in understanding cardiovascular dysfunction and treatment, even though current therapies are largely uniform across genders.